HESTER PHARM share price has plunged 8% and is presently trading at Rs 2,210.0.
Meanwhile, the BSE HEALTHCARE index is at 43,973.0 (up 0.5%).
Among the top losers in the BSE HEALTHCARE index today are AJANTA PHARMA (down 10.3%) and J.B.Chemicals (down 1.4%).
ASTER DM HEALTHCARE (up 3.8%) and ALEMBIC PHARMA (up 2.0%) are among the top gainers today.
Over the last one year, HESTER PHARM has moved up from Rs 1,698.1 to Rs 2,210.0, registering a gain of Rs 512.0 (up 30.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,508.7 to 43,973.0, registering a gain of 54.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 169.5%), SUVEN PHARMACEUTICALS (up 106.6%) and Lupin (up 95.6%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 83,359.2 (up 0.5%).
The top gainers among the BSE Sensex today are NTPC (up 2.8%) and HCl Tech. (up 1.7%). The most traded stocks in the BSE Sensex are NTPC and Tata Steel.
In the meantime, NSE Nifty is at 25,487.1 (up 0.4%). NTPC and LTIMINDTREE are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 67,596.8 to 83,359.2, registering a gain of 15,762.3 points (up 23.3%).
HESTER PHARM net profit grew 24.1% YoY to Rs 66 million for the quarter ended June 2024, compared to a profit of Rs 53 million a year ago. Net sales declined 6.4% to Rs 823 million during the period as against Rs 879 million in April-June 2023.
For the year ended March 2024, HESTER PHARM reported 24.5% decrease in net profit to Rs 212 million compared to net profit of Rs 280 million during FY23. Revenue of the company grew 14.5% to Rs 3,045 million during FY24.
The current Price to earnings ratio of HESTER PHARM, based on rolling 12 month earnings, stands at 105.4.
Equitymaster requests your view! Post a comment on "HESTER PHARM Plunges 8%; BSE HEALTHCARE Index Up 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!